BRPI0816992A2 - Derivado heterocíclico tricícloco, e, composição farmacêutica - Google Patents

Derivado heterocíclico tricícloco, e, composição farmacêutica

Info

Publication number
BRPI0816992A2
BRPI0816992A2 BRPI0816992A BRPI0816992A2 BR PI0816992 A2 BRPI0816992 A2 BR PI0816992A2 BR PI0816992 A BRPI0816992 A BR PI0816992A BR PI0816992 A2 BRPI0816992 A2 BR PI0816992A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
heterocyclic derivative
tricyclic heterocyclic
tricyclic
derivative
Prior art date
Application number
Other languages
English (en)
Inventor
Simon James Anthony Grove
Takao Kiyoi
Ashvinkumar Dhirubhai Mistry
Peter Christopher Ray
Grant Wishart
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of BRPI0816992A2 publication Critical patent/BRPI0816992A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0816992 2007-09-17 2008-09-15 Derivado heterocíclico tricícloco, e, composição farmacêutica BRPI0816992A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07116561 2007-09-17
PCT/EP2008/062229 WO2009037220A1 (en) 2007-09-17 2008-09-15 Tricyclic heterocyclic derivatives

Publications (1)

Publication Number Publication Date
BRPI0816992A2 true BRPI0816992A2 (pt) 2015-03-24

Family

ID=39718515

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816992 BRPI0816992A2 (pt) 2007-09-17 2008-09-15 Derivado heterocíclico tricícloco, e, composição farmacêutica

Country Status (17)

Country Link
US (1) US20100210680A1 (pt)
EP (1) EP2203454A1 (pt)
JP (1) JP5447380B2 (pt)
KR (1) KR20100072027A (pt)
CN (1) CN101801980B (pt)
AR (1) AR068521A1 (pt)
AU (1) AU2008300607B2 (pt)
BR (1) BRPI0816992A2 (pt)
CA (1) CA2698436A1 (pt)
CL (1) CL2008002767A1 (pt)
CO (1) CO6260138A2 (pt)
MX (1) MX2010002900A (pt)
NZ (1) NZ583627A (pt)
PE (1) PE20090704A1 (pt)
RU (1) RU2010115337A (pt)
TW (1) TW200924752A (pt)
WO (1) WO2009037220A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
NZ596827A (en) * 2009-05-22 2014-01-31 Abbott Lab Modulators of 5-ht receptors and methods of use thereof
AU2010353724B2 (en) 2010-05-21 2015-02-12 AbbVie Deutschland GmbH & Co. KG Modulators of 5-HT receptors and methods of use thereof
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CA3093189A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
WO2024091983A1 (en) * 2022-10-25 2024-05-02 Artus Therapeutics, Inc. Therapeutic agents for enhancing epithelial and/or endothelial barrier function
CN116253627A (zh) * 2022-12-27 2023-06-13 大连双硼医药化工有限公司 一种合成2-溴-6-羟基苯甲醛的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132710A (en) 1976-12-20 1979-01-02 Ayerst, Mckenna And Harrison, Ltd. [2]Benzopyrano[3,4-c]pyridines and process therefor
US4132709A (en) * 1976-12-20 1979-01-02 Ayerst, Mckenna & Harrison, Ltd. [2]Benzopyrano[4,3-c]pyridine derivatives and process therefor
NL8005754A (nl) * 1980-10-18 1982-05-17 Akzo Nv Benzo 4,5 pyrano 2,3-c pyrrool derivaten.
US4666916A (en) * 1985-11-08 1987-05-19 Ciba-Geigy Corporation Hexahydro-(1)-benzo-(pyrano and thiopyrano) (4,3-C)pyridines, useful as serotin-2 blocking agents
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
ES2090119T3 (es) * 1988-12-15 1996-10-16 Abbott Lab Agentes selectivos de 5-ht.
GB8917333D0 (en) * 1989-07-28 1989-09-13 Merck Sharp & Dohme Therapeutic agents
CA2118920A1 (en) * 1991-10-24 1993-04-29 Arthur G. Romero Benzo-isoquinoline derivatives and analogs and their use in therapeutics
FR2722194B1 (fr) * 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent

Also Published As

Publication number Publication date
TW200924752A (en) 2009-06-16
JP2010539139A (ja) 2010-12-16
AR068521A1 (es) 2009-11-18
JP5447380B2 (ja) 2014-03-19
MX2010002900A (es) 2010-03-31
RU2010115337A (ru) 2011-10-27
CO6260138A2 (es) 2011-03-22
CL2008002767A1 (es) 2009-03-06
US20100210680A1 (en) 2010-08-19
CN101801980B (zh) 2014-03-12
CN101801980A (zh) 2010-08-11
NZ583627A (en) 2011-08-26
CA2698436A1 (en) 2009-03-26
PE20090704A1 (es) 2009-06-20
AU2008300607B2 (en) 2013-08-22
EP2203454A1 (en) 2010-07-07
WO2009037220A1 (en) 2009-03-26
AU2008300607A1 (en) 2009-03-26
KR20100072027A (ko) 2010-06-29

Similar Documents

Publication Publication Date Title
LTC2140867I2 (lt) Farmacinė kompozicija
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0816992A2 (pt) Derivado heterocíclico tricícloco, e, composição farmacêutica
BRPI0715712A2 (pt) Composição farmacêutica
DK2207773T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
BRPI0719393A2 (pt) Composição farmacêutica
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
BRPI1013642A2 (pt) derivado de triazina e composição farmacêutica compreendendo o mesmo
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0813836A2 (pt) Derivados pirazólicos
DK2254873T3 (da) Benzodiazepinforbindelse og farmaceutisk sammensætning.
BRPI0809346A2 (pt) Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
ATE518837T1 (de) Indazolamidderivate
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
DK2152370T3 (da) Aryletherpyridazinonderivater
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0817833A2 (pt) Composição farmacêutica antimalárica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]